Raymond James & Associates Genmab A/S Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Genmab A/S stock. As of the latest transaction made, Raymond James & Associates holds 169,747 shares of GMAB stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

169,747

Previous 166,149 2.17%

Holding current value

$3.51 Million

Previous $4.18 Million 0.89%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$23.84 - $28.48 $85,776 - $102,471	3,598 Added 2.17%	169,747 $4.14 Million
Q2 2024 Jul 19, 2024	SELL	$25.13 - $30.27 $5,428 - $6,538	-216 Reduced 0.13%	166,149 $4.18 Million
Q1 2024 Apr 22, 2024	SELL	$26.43 - $32.77 $655,173 - $812,335	-24,789 Reduced 12.97%	166,365 $4.98 Million
Q4 2023 Jan 16, 2024	SELL	$27.94 - $35.44 $151,015 - $191,553	-5,405 Reduced 2.75%	191,154 $6.09 Million
Q3 2023 Oct 24, 2023	BUY	$35.27 - $42.24 $84,506 - $101,207	2,396 Added 1.23%	196,559 $6.93 Million
Q2 2023 Jul 25, 2023	SELL	$37.4 - $42.94 $162,989 - $187,132	-4,358 Reduced 2.2%	194,163 $7.38 Million
Q1 2023 Apr 14, 2023	BUY	$34.88 - $43.22 $261,530 - $324,063	7,498 Added 3.93%	198,521 $7.5 Million
Q4 2022 Feb 08, 2023	SELL	$33.8 - $47.06 $815,661 - $1.14 Million	-24,132 Reduced 11.22%	191,023 $8.1 Million
Q3 2022 Oct 25, 2022	SELL	$31.52 - $373.61 $1.06 Million - $12.6 Million	-33,703 Reduced 13.54%	215,155 $6.91 Million
Q2 2022 Aug 12, 2022	BUY	$26.83 - $38.57 $1.15 Million - $1.66 Million	43,043 Added 20.91%	248,858 $8.09 Million
Q1 2022 May 11, 2022	BUY	$30.95 - $39.68 $1.06 Million - $1.36 Million	34,384 Added 20.06%	205,815 $7.45 Million
Q4 2021 Feb 08, 2022	BUY	$35.87 - $47.12 $254,748 - $334,646	7,102 Added 4.32%	171,431 $6.78 Million
Q3 2021 Nov 02, 2021	BUY	$41.55 - $48.72 $409,973 - $480,720	9,867 Added 6.39%	164,329 $7.18 Million
Q2 2021 Aug 11, 2021	BUY	$32.88 - $44.57 $2.31 Million - $3.13 Million	70,219 Added 83.35%	154,462 $6.31 Million
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $194,486 - $279,276	-6,290 Reduced 6.95%	84,243 $2.77 Million
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $403,987 - $489,201	12,002 Added 15.28%	90,533 $3.68 Million
Q3 2020 Nov 04, 2020	BUY	$33.07 - $38.68 $101,888 - $119,173	3,081 Added 4.08%	78,531 $2.88 Million
Q2 2020 Jul 28, 2020	SELL	$20.05 - $33.89 $963,683 - $1.63 Million	-48,064 Reduced 38.91%	75,450 $2.56 Million
Q1 2020 Apr 21, 2020	BUY	$17.15 - $25.22 $63,969 - $94,070	3,730 Added 3.11%	123,514 $2.62 Million
Q4 2019 Feb 12, 2020	BUY	$18.88 - $24.14 $155,439 - $198,744	8,233 Added 7.38%	119,784 $2.68 Million
Q3 2019 Nov 07, 2019	BUY	$18.0 - $21.38 $2.01 Million - $2.38 Million	111,551 New	111,551 $2.26 Million

Others Institutions Holding GMAB

# of Institutions

236

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Genmab A/S Transaction History